{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T06:37:49Z","timestamp":1772087869389,"version":"3.50.1"},"reference-count":28,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T00:00:00Z","timestamp":1772064000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>This study aimed to identify clinical characteristics associated with hemorrhagic events in acute leukemia patients who received anti-tumor therapies and to develop and evaluate a prediction nomogram for hemorrhagic events based on those characteristics.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>This retrospective cohort study included 468 acute leukemia patients, excluding those with acute promyelocytic leukemia, treated at The Shanghai Fifth People\u2019s Hospital and Nanyang Municipal Central Hospital between January 2013 and December 2023. The primary endpoint was World Health Organization (WHO) grade 2 or higher hemorrhagic events related to anti-tumor therapy. Patients were randomly divided into training and test groups at a ratio of 7:3. In the training group, univariable logistic analysis and least absolute shrinkage and selection operator (LASSO) regression were performed to identify significant predictors, which were then used to construct a prediction nomogram for hemorrhage risk. Nomogram performance was evaluated by receiver operating characteristic (ROC) curve analysis, calibration curve analysis, and decision curve analysis (DCA). The following five independent variables were identified as predictors of anti-tumor therapy-related hemorrhagic events in acute leukemia patients and used to develop a prediction nomogram: infection status, types of different hemorrhage prevention drugs and blood products administered, platelet (PLT) transfusion, hematocrit, and PLT count.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Result<\/jats:title>\n                    <jats:p>On ROC curve analysis, the nomogram exhibited satisfactory performance in both the training group [area under the ROC curve (AUC)=0.741] and test group (AUC=0.718). Calibration plots showed a high degree of consistency between the actual and nomogram-predicted survival rates in both groups, and the nomogram showed good clinical utility on DCA. We successfully developed and validated a nomogram for predicting the risk of anti-tumor therapy-related hemorrhage of WHO grade 2 or higher among patients with acute leukemia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This nomogram may provide a practical and user-friendly tool for clinical practice once further validated in perspective large cohort or trials.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2025.1684145","type":"journal-article","created":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T05:29:25Z","timestamp":1772083765000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Nomogram to predict hemorrhage risk related to anti-tumor therapy in patients with acute leukemia"],"prefix":"10.3389","volume":"15","author":[{"given":"Xinxin","family":"Hu","sequence":"first","affiliation":[{"name":"Department of Hematology, Shanghai Fifth People\u2019s Hospital, Fudan University","place":["Shanghai, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"He","sequence":"additional","affiliation":[{"name":"Department of Hematology, Nanyang Municipal Central Hospital","place":["Nanyang, Henan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yinghua","family":"Xie","sequence":"additional","affiliation":[{"name":"Department of Hematology, Shanghai Fifth People\u2019s Hospital, Fudan University","place":["Shanghai, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Zhao","sequence":"additional","affiliation":[{"name":"Clinical Molecular Cytogenetics and Immunology Laboratory, The First Hospital of Lanzhou University","place":["Lanzhou, Gansu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruijuan","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Hematology, Nanyang Municipal Central Hospital","place":["Nanyang, Henan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lijuan","family":"Duan","sequence":"additional","affiliation":[{"name":"Department of Hematology, Nanyang Municipal Central Hospital","place":["Nanyang, Henan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peipei","family":"Mao","sequence":"additional","affiliation":[{"name":"Department of Hematology, Nanyang Municipal Central Hospital","place":["Nanyang, Henan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiyao","family":"Han","sequence":"additional","affiliation":[{"name":"Department of Hematology, Shanghai Fifth People\u2019s Hospital, Fudan University","place":["Shanghai, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yihan","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Hematology, Shanghai Fifth People\u2019s Hospital, Fudan University","place":["Shanghai, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chao","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Hematology, Nanyang Municipal Central Hospital","place":["Nanyang, Henan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01556-7","article-title":"Infectious complications of targeted drugs and biotherapies in acute leukemia. Clinical practice guidelines by the European Conference on Infections in Leukemia (ECIL), a joint venture of the European Group for Blood and Marrow Transplantation (EBMT), the European Organization for Research and Treatment of Cancer (EORTC), the International Immunocompromised Host Society (ICHS) and the European Leukemia Net (ELN)","volume":"36","author":"Maschmeyer","year":"2022","journal-title":"Leukemia"},{"key":"B2","doi-asserted-by":"publisher","first-page":"e725","DOI":"10.1002\/iid3.725","article-title":"Emerging roles of circRNAs in leukemia and the clinical prospects: An update","volume":"11","author":"Deng","year":"2023","journal-title":"Immun Inflammation Dis"},{"key":"B3","doi-asserted-by":"publisher","first-page":"150951","DOI":"10.1016\/j.soncn.2019.150951","article-title":"Adult acute lymphoblastic leukemia: treatment and management updates","volume":"35","author":"Gregory","year":"2019","journal-title":"Semin Oncol Nurs"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26822","article-title":"Acute myeloid leukemia: 2023 update on diagnosis, risk-stratification, and management","volume":"98","author":"Shimony","year":"2023","journal-title":"Am J Hematol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30073-5","article-title":"Cancer registration in China and its role in cancer prevention and control","volume":"21","author":"Wei","year":"2020","journal-title":"Lancet Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000010137","article-title":"The role of thromboelastography in predicting hemorrhage risk in patients with leukemia","volume":"97","author":"Bao","year":"2018","journal-title":"Med (Baltimore)"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1965.03090020019005","article-title":"CAUSES OF DEATH IN ACUTE LEUKEMIA: A TEN-YEAR STUDY OF 414 PATIENTS FROM 1954-1963","volume":"193","author":"Hersh","year":"1965","journal-title":"Jama"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1097\/00005792-197605000-00005","article-title":"Causes of death in adults with acute leukemia","volume":"55","author":"Chang","year":"1976","journal-title":"Med (Baltimore)"},{"key":"B10","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s13045-021-01077-3","article-title":"Novel agents and regimens for hematological Malignancies: recent updates from 2020 ASH annual meeting","volume":"14","author":"Hou","year":"2021","journal-title":"J Hematol Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020001920","article-title":"American Society of Hematology 2020 guidelines for treating newly diagnosed acute myeloid leukemia in older adults","volume":"4","author":"Sekeres","year":"2020","journal-title":"Blood Adv"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1212772","article-title":"A no-prophylaxis platelet-transfusion strategy for hematologic cancers","volume":"368","author":"Stanworth","year":"2013","journal-title":"N Engl J Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S246385","article-title":"Mean platelet volume has prognostic value in chronic lymphocytic leukemia","volume":"12","author":"Masternak","year":"2020","journal-title":"Cancer Manag Res"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2010.05.022","article-title":"Significance of fibrinogen, D-dimer, and LDH levels in predicting the risk of bleeding in patients with acute promyelocytic leukemia","volume":"35","author":"Kim","year":"2011","journal-title":"Leuk Res"},{"key":"B15","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1186\/s13613-017-0341-y","article-title":"Risks of bleeding and thrombosis in intensive care unit patients with haematological Malignancies","volume":"7","author":"Russell","year":"2017","journal-title":"Ann Intensive Care"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-09-178236","article-title":"A randomized controlled trial comparing standard- and low-dose strategies for transfusion of platelets (SToP) to patients with thrombocytopenia","volume":"113","author":"Heddle","year":"2009","journal-title":"Blood"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1111\/trf.12058","article-title":"The challenges of measuring bleeding outcomes in clinical trials of platelet transfusions","volume":"53","author":"Estcourt","year":"2013","journal-title":"Transfusion"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2017.1391216","article-title":"Cytarabine and daunorubicin for the treatment of acute myeloid leukemia","volume":"18","author":"Murphy","year":"2017","journal-title":"Expert Opin Pharmacother"},{"key":"B19","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/s41408-020-00376-1","article-title":"New directions for emerging therapies in acute myeloid leukemia: the next chapter","volume":"10","author":"Daver","year":"2020","journal-title":"Blood Cancer J"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2021.1924053","article-title":"Clinical challenges and promising therapies for chemotherapy-induced thrombocytopenia","volume":"14","author":"Al-Samkari","year":"2021","journal-title":"Expert Rev Hematol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1111\/liv.14034","article-title":"Coagulation failure is associated with bleeding events and clinical outcome during systemic inflammatory response and sepsis in acute-on-chronic liver failure: An observational cohort study","volume":"39","author":"Premkumar","year":"2019","journal-title":"Liver Int"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021006166","article-title":"Prediction of life-threatening and disabling bleeding in patients with AML receiving intensive induction chemotherapy","volume":"6","author":"Versluis","year":"2022","journal-title":"Blood Adv"},{"key":"B23","doi-asserted-by":"publisher","first-page":"7828230","DOI":"10.1155\/2022\/7828230","article-title":"Analysis of risk factors of coagulation dysfunction and hemorrhage in newly diagnosed hyperleukocytic acute myeloma leukemia","volume":"2022","author":"Xu","year":"2022","journal-title":"Contrast Media Mol Imaging"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-020-04298-7","article-title":"Thrombocytopenia and the effect of platelet transfusions on the occurrence of intracranial hemorrhage in patients with acute leukemia - a nested case-control study","volume":"100","author":"Cornelissen","year":"2021","journal-title":"Ann Hematol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1515\/cclm-2019-0380","article-title":"The role of platelets in bleeding in patients with thrombocytopenia and hematological disease","volume":"57","author":"Vinholt","year":"2019","journal-title":"Clin Chem Lab Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2022.942100","article-title":"Development and validation of a nomogram to predict the 30-day mortality risk of patients with intracerebral hemorrhage","volume":"16","author":"Zou","year":"2022","journal-title":"Front Neurosci"},{"key":"B27","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1186\/s12876-020-01464-z","article-title":"Establishment of prognostic nomogram for elderly colorectal cancer patients: a SEER database analysis","volume":"20","author":"Yu","year":"2020","journal-title":"BMC Gastroenterol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2023-072632","article-title":"Nomogram predicting overall prognosis for invasive micropapillary carcinoma of the breast: a SEER-based population study","volume":"13","author":"Liu","year":"2023","journal-title":"BMJ Open"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1684145\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T05:29:26Z","timestamp":1772083766000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1684145\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,26]]},"references-count":28,"alternative-id":["10.3389\/fonc.2025.1684145"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1684145","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,26]]},"article-number":"1684145"}}